Effects of Community-Wide Vaccination with PCV-7 on Pneumococcal Nasopharyngeal Carriage in The Gambia: A Cluster-Randomized Trial

English version České info

Background:
Introduction of pneumococcal conjugate vaccines (PCVs) of limited valency is justified in Africa by the high burden of pneumococcal disease. Long-term beneficial effects of PCVs may be countered by serotype replacement. We aimed to determine the impact of PCV-7 vaccination on pneumococcal carriage in rural Gambia.

Methods and Findings:
A cluster-randomized (by village) trial of the impact of PCV-7 on pneumococcal nasopharyngeal carriage was conducted in 21 Gambian villages between December 2003 to June 2008 (5,441 inhabitants in 2006). Analysis was complemented with data obtained before vaccination. Because efficacy of PCV-9 in young Gambian children had been shown, it was considered unethical not to give PCV-7 to young children in all of the study villages. PCV-7 was given to children below 30 mo of age and to those born during the trial in all study villages. Villages were randomized (older children and adults) to receive one dose of PCV-7 (11 vaccinated villages) or meningococcal serogroup C conjugate vaccine (10 control villages). Cross-sectional surveys (CSSs) to collect nasopharyngeal swabs were conducted before vaccination (2,094 samples in the baseline CSS), and 4–6, 12, and 22 mo after vaccination (1,168, 1,210, and 446 samples in CSS-1, -2, and -3, respectively).

A time trend analysis showed a marked fall in the prevalence of vaccine-type pneumococcal carriage in all age groups following vaccination (from 23.7% and 26.8% in the baseline CSS to 7.1% and 8.5% in CSS-1, in vaccinated and control villages, respectively). The prevalence of vaccine-type pneumococcal carriage was lower in vaccinated than in control villages among older children (5 y to <15 y of age) and adults (≥15 y of age) at CSS-2 (odds ratio [OR] = 0.15 [95% CI 0.04–0.57] and OR = 0.32 [95% CI 0.10–0.98], respectively) and at CSS-3 (OR = 0.37 [95% CI 0.15–0.90] for older children, and 0% versus 7.6% for adults in vaccinated and control villages, respectively). Differences in the prevalence of non-vaccine-type pneumococcal carriage between vaccinated and control villages were small.

Conclusions:
Vaccination of Gambian children reduced vaccine-type pneumococcal carriage across all age groups, indicating a “herd effect” in non-vaccinated older children and adults. No significant serotype replacement was detected.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Effects of Community-Wide Vaccination with PCV-7 on Pneumococcal Nasopharyngeal Carriage in The Gambia: A Cluster-Randomized Trial. PLoS Med 8(10): e32767. doi:10.1371/journal.pmed.1001107
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001107

Souhrn

Zdroje

1. O'BrienKLWolfsonLJWattJPHenkleEDeloria-KnollM 2009 Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374 893 902 doi:10.1016/S0140-6736(09)61204-6

2. BlackSBShinefieldHRLingSHansenJFiremanB 2002 Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21 810 815 doi:10.1097/01.inf.0000027926.99356.4c

3. LexauCALynfieldRDanilaRPilishviliTFacklamR 2005 Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 2043 2051 doi:10.1001/jama.294.16.2043

4. WhitneyCGFarleyMMHadlerJHarrisonLHBennettNM 2003 Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 1737 1746 doi:10.1056/NEJMoa022823

5. PilishviliTLexauCFarleyMMHadlerJHarrisonLH 2010 Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201 32 41 doi:10.1086/648593

6. WhitneyCGPilishviliTFarleyMMSchaffnerWCraigAS 2006 Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 1495 1502 doi:10.1016/S0140-6736(06)69637-2

7. CheungYBZamanSMNsekpongEDVan BenedenCAAdegbolaRA 2009 Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian children who participated in a 9-valent pneumococcal conjugate vaccine trial and in their younger siblings. Pediatr Infect Dis J 28 990 995 doi:10.1097/INF.0b013e3181a78185

8. DaganRGivon-LaviNZamirOSikuler-CohenMGuyL 2002 Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 185 927 936 doi:10.1086/339525

9. HanageWPFinkelsteinJAHuangSSPeltonSIStevensonAE 2010 Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2 80 84 doi:10.1016/j.epidem.2010.03.005

10. HanquetGKisslingEFenollAGeorgeRLepoutreA 2010 Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis 16 1428 1439

11. HsiehYCLinPYChiuCHHuangYCChangKY 2009 National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine 27 5513 5518 doi:10.1016/j.vaccine.2009.06.091

12. van GilsEJVeenhovenRHHakERodenburgGDKeijzersWC 2010 Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA 304 1099 1106 doi:10.1001/jama.2010.1290

13. FlascheSVan HoekAJSheasbyEWaightPAndrewsN 2011 Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 8 e1001017 doi:10.1371/journal.pmed.1001017

14. RodenburgGDde GreeffSCJansenAGde MelkerHESchoulsLM 2010 Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 16 816 823

15. BerkleyJALoweBSMwangiIWilliamsTBauniE 2005 Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 352 39 47 doi:10.1056/NEJMoa040275

16. RocaASigauqueBQuintoLMandomandoIVallesX 2006 Invasive pneumococcal disease in children<5 years of age in rural Mozambique. Trop Med Int Health 11 1422 1431 doi:10.1111/j.1365-3156.2006.01697.x

17. RocaASigauqueBQuintoLMoraisLBerengueraA 2010 Estimating the vaccine-preventable burden of hospitalized pneumonia among young Mozambican children. Vaccine 28 4851 4857 doi:10.1016/j.vaccine.2010.03.060

18. ScottJA 2007 The preventable burden of pneumococcal disease in the developing world. Vaccine 25 2398 2405 doi:10.1016/j.vaccine.2006.09.008

19. UsenSAdegbolaRMulhollandKJaffarSHiltonS 1998 Epidemiology of invasive pneumococcal disease in the Western Region, The Gambia. Pediatr Infect Dis J 17 23 28

20. CuttsFTZamanSMEnwereGJaffarSLevineOS 2005 Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365 1139 1146 doi:10.1016/S0140-6736(05)71876-6

21. KlugmanKPMadhiSAHuebnerREKohbergerRMbelleN 2003 A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 1341 1348 doi:10.1056/NEJMoa035060

22. VallesXFlanneryBRocaAMandomandoISigauqueB 2006 Serotype distribution and antibiotic susceptibility of invasive and nasopharyngeal isolates of Streptococcus pneumoniae among children in rural Mozambique. Trop Med Int Health 11 358 366 doi:10.1111/j.1365-3156.2006.01565.x

23. HillPCAkisanyaASankarehKCheungYBSaakaM 2006 Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers. Clin Infect Dis 43 673 679 doi:10.1086/506941

24. HillPCCheungYBAkisanyaASankarehKLahaiG 2008 Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a longitudinal study. Clin Infect Dis 46 807 814 doi:10.1086/528688

25. AbdullahiONyiroJLewaPSlackMScottJA 2008 The descriptive epidemiology of Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage in children and adults in Kilifi district, Kenya. Pediatr Infect Dis J 27 59 64 doi:10.1097/INF.0b013e31814da70c

26. HillPCTownendJAntonioMAkisanyaBEbrukeC 2010 Transmission of Streptococcus pneumoniae in rural Gambian villages: a longitudinal study. Clin Infect Dis 50 1468 1476 doi:10.1086/652443

27. CampbellJDKotloffKLSowSOTapiaMKeitaMM 2004 Invasive pneumococcal infections among hospitalized children in Bamako, Mali. Pediatr Infect Dis J 23 642 649

28. DarboeMKFulfordAJSeckaOPrenticeAM 2010 The dynamics of nasopharyngeal streptococcus pneumoniae carriage among rural Gambian mother-infant pairs. BMC Infect Dis 10 195 doi:10.1186/1471-2334-10-195

29. SingletonRJHennessyTWBulkowLRHammittLLZulzT 2007 Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 1784 1792 doi:10.1001/jama.297.16.1784

30. Schim van der LoeffMFSarge-NjieRCeesaySAwasanaAAJayeP 2003 Regional differences in HIV trends in The Gambia: results from sentinel surveillance among pregnant women. AIDS 17 1841 1846 doi:10.1097/01.aids.0000076303.76477.49

31. O'BrienKLNohynekH 2003 Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 22 e1 e11 doi:10.1097/01.inf.0000049347.42983.77

32. BrueggemannABGriffithsDTMeatsEPetoTCrookDW 2003 Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 187 1424 1432 doi:10.1086/374624

33. Lloyd-EvansNO'DempseyTJBaldehISeckaODembaE 1996 Nasopharyngeal carriage of pneumococci in Gambian children and in their families. Pediatr Infect Dis J 15 866 871

34. ObaroSKAdegbolaRABanyaWAGreenwoodBM 1996 Carriage of pneumococci after pneumococcal vaccination. Lancet 348 271 272

35. MillarEVWattJPBronsdonMADallasJReidR 2008 Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 47 989 996 doi:10.1086/591966

36. AdegbolaRAHillPCSeckaOIkumapayiUNLahaiG 2006 Serotype and antimicrobial susceptibility patterns of isolates of Streptococcus pneumoniae causing invasive disease in The Gambia 1996–2003. Trop Med Int Health 11 1128 1135 doi:10.1111/j.1365-3156.2006.01652.x

37. GessnerBDMuellerJEYaroS 2010 African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults. BMC Infect Dis 10 22 doi:10.1186/1471-2334-10-22

38. HausdorffWP 2007 The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 25 2406 2412 doi:10.1016/j.vaccine.2006.09.009

39. LeimkugelJAdamsFAGagneuxSPflugerVFlierlC 2005 An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J Infect Dis 192 192 199 doi:10.1086/431151

40. DugganST 2010 Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13(R)]. Drugs 70 1973 1986 doi:10.2165/11205110-000000000-00000

41. EspositoSTanseySThompsonARazmpourALiangJ 2010 Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 17 1017 1026 doi:10.1128/CVI.00062-10

42. YehSHGurtmanAHurleyDCBlockSLSchwartzRH 2010 Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 126 e493 e505 doi:10.1542/peds.2009-3027